Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Joseph

Physician Assistant Grand Rapids, MI Physician Assistant

NPI 1366814931 CMS profile 10917029

2080 Union Ave Se Ste A, Grand Rapids, MI 49507

Open in the dashboard

General payments

$82,272

782 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Joseph of Grand Rapids, MI is reported in the CMS Open Payments database as having received $82,272 across 782 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,186 243
2024 General $21,050 191
2023 General $12,859 152
2022 General $2,885 113
2021 General $2,292 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Joseph
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Melissa Joseph were reported at $43,186. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Melissa Joseph Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,292 $132 $37–$438 $132
2022 $2,885 $155 $48–$522 $149
2023 $12,859 $167 $52–$557 $160
2024 $21,050 $178 $55–$600 $164
2025 $43,186 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $30,611 169 payments
  2. ITI, Inc. $26,028 188 payments
  3. Alkermes, Inc. $10,185 70 payments
  4. Axsome Therapeutics, Inc. $6,687 15 payments
  5. Neurocrine Biosciences, Inc. $2,400 68 payments
  6. Otsuka America Pharmaceutical, Inc. $1,862 64 payments
  7. Teva Pharmaceuticals USA, Inc. $1,712 54 payments
  8. Indivior Inc. $701 45 payments
  9. Lundbeck LLC $490 32 payments
  10. Supernus Pharmaceuticals, Inc. $343 29 payments
  11. Other $1,255 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,188 35 payments
  2. Food and Beverage $16,798 687 payments
  3. Consulting Fee $11,898 6 payments
  4. Travel and Lodging $4,912 45 payments
  5. Education $478 9 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $23,093 59 payments
  2. VRAYLAR Neuroscience $21,744 121 payments
  3. LYBALVI Cns $9,576 51 payments
  4. LYBALVI Cns $9,207 31 payments
  5. LYBALVI Cns $9,159 28 payments
  6. LYBALVI Cns $9,159 28 payments
  7. VRAYLAR Neuroscience $8,866 48 payments
  8. Auvelity $6,658 14 payments
  9. CAPLYTA Psychiatry $2,935 129 payments
  10. INGREZZA $1,781 57 payments
  11. Other $10,543 426 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

258

Median for Physician Assistant: 241

Drug cost

$67,186

Median for Physician Assistant: $4,110

Branded share of claims

47.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 18 $47,459
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 20 $5,357
Clozapine Generic 22 $4,721
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 53 $3,521
Quetiapine Fumarate Er Quetiapine Fumarate Brand 19 $3,100
Oxcarbazepine Generic 11 $1,373
Gabapentin Generic 17 $410
Quetiapine Fumarate Generic 12 $332
Bupropion Xl Bupropion Hcl Brand 13 $329
Aripiprazole Generic 14 $206

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$11,716 — —
Auvelity
$6,489 — —
CAPLYTA
$943 — —
INGREZZA
$418 — —
REXULTI
$241 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

782 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record